Registration for
Towards the Future of Biopharma: Insights into Oligonucleotide Therapeutics
Dive into the world of biopharma analysis with us as we cover the essential aspects of oligonucleotides, a group of rapidly advancing drugs that offers promising treatments and holds great potential for personalized medicines.
We will showcase state-of-the-art solutions that support the entire workflow employed by Contract Drug Manufacturing Organizations (CDMOs), from R&D to validation and manufacturing. Get valuable insights into biopharmaceutical drug development and delve into the capabilities of our solutions, including our Nexera XS inert system, LCMS-9050 QTOF, and the latest LabSolutions Insight Biologics software.
Let’s work towards shaping the future of medicine together. Register now to secure your seat.
Learning Objectives:
Neil Loftus
General Manager, Mass Spectrometry Business Unit (Overseas)
Shimadzu Corporation
Neil Loftus is an expert in developing new mass spectrometry technologies and innovative data processing workflows to solve complex analytical problems.
As the General Manager of the Mass Spectrometry Business Unit (Overseas) at Shimadzu Corporation, he brings a wealth of experience to his current role.
Neil's professional journey began at the London Hospital Medical College, where he focused on academic and pharmaceutical research applications in metabolism and pharmacokinetics.
He then continued his work in clinical quantitative bioanalysis and metabolite identification in an industrial setting before transitioning into mass spectrometry.
Throughout Neil’s career, he has remained deeply involved in mass spectrometry research and development.
His contributions include publishing scientific papers on pharmaceutical metabolite identification and biomarker research, as well as generating new solutions to change the way we think about data and solve problems that matter.
Max Kosok
Senior Product Specialist (LCMS)
Shimadzu (Asia Pacific) Pte Ltd
With more than 14 years of experience, Dr. Kosok is a passionate expert in mass spectrometry. He has received is PhD from National University of Singapore in Biochemistry doing proteomics research on triple negative breast cancer by high resolution LCMS. In 2020, he joined Shimadzu to deliver end-to-end LCMS application solutions for customers. In his current role as a Product Specialist for LCMS and previously as an application chemist, Dr. Kosok has worked with various pharma and biopharma customers. He has supported a multitude of applications from impurity analysis to biomolecule characterization, particularly on Shimadzu’s LCMS QTOF technology.